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Abstract 30 
Resistance to therapy and lack of curative treatments for metastatic breast cancer suggest that current therapies 31 
may be missing the subpopulation of chemo- and radio-resistant cancer stem cells (CSC). The ultimate success 32 
of any treatment may well rest on CSC eradication, but specific anti-CSC therapies are still limited. A 33 
comparison of the transcriptional profiles of murine Her2+ breast tumor TUBO cells and their derived CSC-34 
enriched tumorspheres has identified xCT, the functional subunit of the cystine/glutamate antiporter system xc-, 35 
as a surface protein that is upregulated specifically in tumorspheres. We validated this finding by 36 
cytofluorimetric analysis and immunofluorescence in TUBO-derived tumorspheres and in a panel of mouse and 37 
human triple negative breast cancer (TNBC) cell-derived tumorspheres. We further show that downregulation 38 
of xCT impaired tumorsphere generation and altered CSC intracellular redox balance in vitro, suggesting that 39 
xCT plays a functional role in CSC biology. DNA vaccination-based immunotargeting of xCT in mice 40 
challenged with syngeneic tumorsphere-derived cells delayed established subcutaneous tumor growth and 41 
strongly impaired pulmonary metastasis formation by generating anti-xCT antibodies able to alter CSC self-42 
renewal and redox balance. Finally, anti-xCT vaccination increased CSC chemosensitivity to doxorubicin in 43 
vivo, indicating that xCT immunotargeting may be an effective adjuvant to chemotherapy. 44 
 45 
Precis  46 
Immunotargeting of breast cancer stem-like cells can sensitize them to chemotherapy, offering an effective 47 
strategy to overcome drug resistance and limit metastatic progression. 48 
49 
 4
Introduction  50 
Despite recent advances in breast cancer management resulting in a decrease in overall mortality (1), minimal 51 
residual disease and local and distant post-treatment recurrences are still major obstacles to complete remission. 52 
According to the cancer stem cell (CSC) model, these residual elements are caused by a stem-like 53 
subpopulation of tumor cells that are endowed with self-renewal and multi-lineage differentiation capabilities, 54 
chemo- and radio-resistance and the ability to give metastases (2). The therapeutic implication of CSC model is 55 
that a tumor needs to be deprived of its CSC population to be completely eradicated. Novel anticancer strategies 56 
must therefore be developed to face this new challenge. 57 
Active immunotherapy, i.e. vaccination, is an attractive approach to target CSC. Preclinical studies have shown 58 
that CSC are immunogenic and a more effective antigen source for inducing protective anti-tumor immunity in 59 
mice than unselected tumor cells (3). Several clinical trials in which CSC lysate or mRNA are used to pulse or 60 
transfect autologous dendritic cells (DC), that are then injected back into the patients, are currently underway in 61 
various tumor settings (4). However, this technique presents the difficulty of setting up standardized functional 62 
DC production procedures (5). A promising alternative can be found in powerful and versatile DNA-based 63 
vaccines which combines lower manufacturing costs and more standardized production processes while also 64 
inducing strong immunological responses against tumor antigens. Nevertheless, one must identify a suitable 65 
target to develop a DNA-based vaccine; as no consensus on the expression of specific vaccination targets by 66 
CSC currently exists, pre-clinical screening by high-throughput technologies can be of use in uncovering 67 
antigens for CSC-targeted genetic vaccines.  68 
We have compared the transcription profile of the murine Her2+ breast cancer TUBO cell line (6) with that of 69 
its CSC-enriched tumorspheres in order to identify antigens expressed by mammary CSC. Among the genes 70 
upregulated in tumorspheres and associated with poor prognosis in several datasets of human mammary cancer, 71 
we focused on xCT. It is the light chain of the antiporter system xc-, which imports the aminoacid cystine into 72 
cells in exchange with glutamate. Cystine is the rate-limiting substrate for the synthesis of the antioxidant 73 
glutathione (GSH), which is known to be involved in the detoxification of reactive oxygen species (ROS) (7). 74 
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xCT is highly expressed by a variety of malignant tumors (7-12) and plays an important role in cancer growth, 75 
progression, metastatic dissemination (13-15) and drug resistance (16). Moreover, its membrane expression is 76 
stabilized via direct interaction with a CD44 variant (13), while targeting xCT has been found to deplete 77 
undifferentiated CD44v-expressing cancer cells in a xenografted model of head and neck squamous cell 78 
carcinoma, sensitizing the tumor to other therapies (17). 79 
We herein report that xCT upregulation is a general feature of breast CSC and that plays a functional role in 80 
CSC biology and intracellular redox balance. We demonstrate that anti-xCT DNA vaccination slows established 81 
subcutaneous tumor growth, efficiently impairs lung metastasis formation and increases CSC chemosensitivity, 82 
thus making it a novel therapeutic approach for breast cancer treatment. 83 
84 
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Materials and Methods 85 
Cell and tumorsphere cultures 86 
MDA-MB-231, HCC-1806 and 4T1 cells were purchased from ATCC (LGC Standards) and cultured as in (18). 87 
NIH/3T3 cells were cultured as in (19). Cells were passaged in our laboratory for fewer than six months after 88 
their resuscitation. TUBO cells and tumorspheres were generated as in (18). Human cell lines were tested 89 
utilizing Short Tandem Repeat (STR) profiling. 90 
FACS analysis 91 
Cells and tumorspheres were stained with AlexaFluor647-anti-Sca-1, PE-anti-CD44 and PE/Cy7-anti-CD24 92 
(Biolegend), and with goat anti-xCT (Santa Cruz Biotechnology) antibodies followed by rabbit FITC-anti-goat 93 
Ig (Dako), or with Aldefluor kit (StemCell Technologies), as in (18). To quantify anti-xCT antibody titers, 94 
tumorsphere-derived and NIH/3T3 cells were incubated with sera of vaccinated mice and subsequently with 95 
rabbit FITC-anti-mouse Ig (Dako). Cells were stained with 2',7'-dihydrochlorofluorescein diacetate (DHCF-DA, 96 
Sigma-Aldrich) as in (20). All samples were analyzed on a CyAnADP Flow Cytometer, using Summit 4.3 97 
software (Beckman Coulter). 98 
Fluorescent microscopy 99 
Tumor microarrays (TMA) (Biochain # T8234700-2, lot # B406087, and Biochain # T6235086-5, lot # 100 
B112136) of normal or tumor human tissues were blocked in 3%H2O2 (Sigma-Aldrich), followed by 1%BSA, 101 
and then incubated with anti-xCT or isotype-matched control antibodies (Abcam). The signal was amplified as 102 
in (21) and sections were fixed in 1%formaldehyde (Sigma-Aldrich), counterstained with DAPI (Sigma-103 
Aldrich) and mounted in Mowiol® (Calbiochem). Images were acquired using a confocal microscope LSM700 104 
and Zen software 7.0.0.285 (Zeiss). Slides were scanned on a slide scanner (Hamamatsu Nanozoomer 2.0RS) 105 
using the Calopix software. xCT+ cell percentage was defined by quantifying blue (nuclei) and red (xCT) 106 
surface areas and calculated as the ratio of xCT expression (i.e. xCT stained surface/xCT+nuclei surface). 107 
Tumorspheres were cytospinned to glass slides, fixed in 4%formaldehyde and then incubated with rabbit anti-108 
OCT4 (Abcam), rat PE-anti-Sca-1 (Santa Cruz biotechnology), mouse APC/eFluor780-anti-Thy1.1 109 
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(eBioscience) or the matched isotype control antibodies. Cytospinned tumorspheres or NIH/3T3 cultured on 110 
glass coverslips were stained with IgG purified from immunized mice sera and then with rabbit AlexaFluor488-111 
anti-mouse or goat Texas red-anti-rabbit secondary antibodies (Life Technologies). Images were acquired on 112 
ApoTome system and AxioVision Release4.8 software (Zeiss). 113 
In vitro cytotoxicity 114 
24 hours after TUBO cells and tumorspheres seeding in 96-well plates, scalar doses of doxorubicin or 115 
sulfasalazine (SASP) (Sigma-Aldrich) were added and incubated at 37°C for 72 hours. Cytotoxicity was 116 
evaluated with MTT using the Cell Proliferation Kit I (Roche Diagnostics). 117 
RNA interference 118 
xCT downregulation in tumorspheres was performed using a pool of specific siRNAs, or scrambled siRNAs 119 
(Invitrogen Corp.), as in (18). 120 
SASP effects on tumorsphere formation 121 
Dissociated tumorspheres were cultured with scalar doses of SASP or its diluent DMSO (Sigma-Aldrich), and 122 
the total number of tumorspheres/well was counted 5 days later. 123 
Measurement of ROS and GSH 124 
ROS amount was analyzed as 2',7'-dichlorofluorescin (DCF) formation in cells incubated with 5μM DHCF-DA 125 
for 20 minutes at 37°C using the Luminescence Spectrometer LS 55 (Perkin–Elmer), quantified using a DCF 126 
standard curve and expressed as pmol DCF formed/min/mg protein (22). GSH content was assessed by 127 
determining non-protein sulphydryl content, as in (23), and calculated using a GSH standard curve. Results are 128 
expressed as μg GSH/mg of cellular proteins. 129 
Plasmids 130 
The cDNA sequence for mouse xCT (NM_011990.2), in the pDream2.1 plasmid (GenScript), was cloned in a 131 
pVAX1 (Invitrogen) plasmid (pVAX1-xCT), sequenced (BMR Genomics), and produced with EndoFree 132 
Plasmid Giga kits (Qiagen Inc.). 133 
Immune sera effect on tumorsphere formation 134 
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Serum IgG from vaccinated mice were purified using the Melon Gel purification kit (Thermo Scientific) and 135 
incubated with tumorsphere-derived cells. After 5 days, spheres were counted and analyzed for CSC markers 136 
expression and ROS production by FACS.  137 
In Vivo Treatments 138 
Wild type (Charles River Laboratories) and Ig µ-chain gene knocked out (BALB-µIgKO) (24) BALB/c mice 139 
were maintained at the Molecular Biotechnology Center, University of Torino, and treated in accordance with 140 
University Ethical Committee and European guidelines under Directive 2010/63. Vaccination, performed either 141 
before or after tumor challenge, consisted of two i.m. electroporation at two weeks interval, of pVAX1 or 142 
pVAX1-xCT plasmids as previously described (25). 143 
Primary s.c. tumors were induced by injecting 1x104 TUBO or 4T1 tumorsphere-derived cells. Some tumors 144 
were explanted and tumorspheres generated as in (26). Lung metastases were induced either by injecting i.v. 145 
5x104 TUBO tumorsphere-derived cells or by injecting s.c. 1x104 4T1 tumorsphere-derived cells. In the latter 146 
case, lungs were removed when s.c. tumors reached 10 mm mean diameter. Micrometastases were counted on a 147 
Nikon SMZ1000 stereomicroscope (Mager Scientific). 148 
Doxorubicin treatment consisted of the i.v. administration of a total dose of 10 mg/Kg either in a single 149 
injection or in two administration at a week interval.  150 
Statistical analysis  151 
Differences in latency, sphere formation, protein expression, GSH and ROS levels and metastasis number were 152 
evaluated using a Student’s t-test. Data are shown as the mean ± SEM unless otherwise stated. Values of P 153 
<0,05 were considered significant. 154 
155 
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xCT is upregulated in breast CSC 156 
To identify the transcripts associated with mouse and human mammary CSC, we compared the transcription 157 
profile of Her2+ murine TUBO cells which had been cultured as an epithelial monolayer, with the profiles of the 158 
first three in vitro passages of their derived tumorspheres (P1, P2 and P3) using MouseWG-6 v2.0 Illumina 159 
beadchips (GSE21451) (Supplementary Figure 1A). This analysis uncovered a cluster of transcripts whose 160 
expression rose, as well as three clusters whose expression decreased from TUBO through P1 to P3 cells 161 
(Supplementary Figure 1B). 162 
We devised a ranking procedure according to the clinical outcome (CO) of tumors expressing the transcripts 163 
that we found increased in tumorspheres (27), using data from six public human breast cancer datasets (see 164 
Supplementary methods). One of the genes with the best CO score was xCT (7) (Slc7a11, Supplementary 165 
Figure 1C), whose expression increased progressively from TUBO to P3 tumorspheres, as confirmed by FACS 166 
(Figure 1A) and qPCR (Supplementary Figure 2) analyses. Interestingly, most P3-derived cells that express the 167 
stem cell marker Sca-1 (26) are also xCT+ (Figure 1B). The immunofluorescence analysis revealed widespread 168 
xCT positivity in tumorspheres that are essentially composed of CSC, as confirmed by Sca-1, OCT4 and Thy1.1 169 
marker expression patterns (Figure 1C). xCT upregulation is a feature of breast CSC and is not due to 170 
tumorsphere culture conditions, since it was also observed on the small CD44highCD24low CSC population 171 
present in TUBO cells (Figure 1D). Moreover, xCT upregulationis not restricted to TUBO-derived CSC as it 172 
was also observed in tumorspheres derived from mouse (4T1) and human (HCC-1806 and MDA-MB-231) 173 
TNBC cell lines (Figure 1E), suggesting that xCT may be a hallmark of breast cancer CSC. 174 
xCT expression in the TMA of normal and neoplastic samples was evaluated to address its distribution in 175 
human cancers. xCT expression was low in normal mammary glands (Figure 1F, left panel) as it was in the 176 
other normal tissues tested (Supplementary Figure 3A). By contrast, xCT was expressed at high levels in many 177 
neoplastic tissues (Supplementary Figure 3B), including hyperplastic mammary lesions and invasive ductal 178 
breast carcinomas (IDC) (Figure 1F, middle and right panels) displaying a pattern in which it is confined to 179 
neoplastic cells. In particular, we found xCT expression in 62% of Her2+, 57% of estrogen/progesterone 180 
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receptor+ Her2- (ER/PR+Her2-), and 35% of TNBC samples (Figure 1G), suggesting that xCT may well be a 181 
commonly upregulated target in breast cancers. 182 
xCT downregulation impairs tumorsphere generation and alters intracellular redox balance  183 
A MTT test was performed on TUBO cells and tumorspheres that had either been treated or not with scalar 184 
doses of xCT inhibitor SASP (28). While SASP did not decrease TUBO cell viability, except for the highest 185 
dose (100 μM; IC50 126,1 ± 25,7 μM; Figure 2A), tumorsphere viability was inhibited in a dose dependent 186 
manner (IC50 51,6 ± 3,5 μM; Figure 2B), suggesting that CSC are sensitive to xCT inhibition. Similarly, xCT 187 
silencing through a pool of specific siRNAs impaired tumorspheres but not TUBO cell viability (Figures 2A, 188 
B). Moreover, SASP treatment and xCT silencing impaired tumorsphere generation (Figure 2C, D). FACS 189 
analyses performed 24 hours after siRNA transfection showed that the reduction in xCT+ cells (Figure 2E, F) is 190 
accompanied by a reduction in CSC, i.e. Sca1+ and CD44high/CD24low cells (Figure 2F). On the contrary, xCT 191 
overexpression increases colony generating ability, as confirmed by the higher number of colonies generated in 192 
soft agar by NIH/3T3 and HEK-293 cells transfected with xCT when compared to the corresponding cells 193 
transfected with empty plasmids (Supplementary Figure 4). Taken together, these data suggest that xCT plays 194 
an important role in CSC maintenance and sphere generation.  195 
As xCT is an important determinant of redox balance (13), we evaluated GSH and ROS levels in TUBO cells 196 
and tumorspheres. GSH amount was significantly greater in tumorspheres than in TUBO cells (Figure 2G), 197 
whereas ROS levels were lower (Figure 2H). xCT downregulation caused a significant decrease in GSH and an 198 
increase in ROS levels (Figure 2G, H) as compared to controls, suggesting that CSC have a higher ROS defense 199 
capability than epithelial tumor cells. 200 
Anti-xCT vaccination induces antibodies that inhibit CSC 201 
BALB/c mice were vaccinated with either pVAX1-xCT or pVAX1 to evaluate whether xCT is a potential target 202 
for cancer immunotherapy. No T-cell response was observed against the H-2Kd dominant mouse xCT peptide 203 
(Supplementary Figure 5A, B). Tumorsphere-derived cells were stained with the sera of vaccinated mice to 204 
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evaluate their humoral response, and specific antibody binding was analyzed by FACS. pVAX1-xCT 205 
vaccination induced the production of CSC-binding antibodies, which were not detectable in empty pVAX1 206 
vaccinated mouse sera (Figure 3A-C). These results were confirmed by the ability of purified IgG, from 207 
pVAX1-xCT vaccinated mouse sera, to stain tumorspheres (Figure 3D). These antibodies are specific for xCT, 208 
since no binding was observed in NIH/3T3 cells negative for xCT expression (Figure 3E-H). 209 
Of note, TUBO cells incubated with IgG purified from pVAX1-xCT vaccinated mice displayed reduced sphere-210 
generation ability (Figure 3I), a lower percentage of stem cell marker positive cells (Figure 3L), but increased 211 
ROS content as compared to control IgG (Figure 3M). 212 
These results suggest that anti-xCT vaccination induces antibodies targeting xCT, thus affecting self-renewal 213 
and ROS production in CSC. 214 
Anti-xCT vaccination slows in vivo breast tumor growth  215 
TUBO-derived tumorspheres were s.c. implanted into BALB/c mice that were vaccinated when tumors reached 216 
2 or 4 mm mean diameter to evaluate whether xCT immune-targeting hinders breast cancer growth (Figure 4A-217 
D). Tumors grew progressively in the pVAX1 group of 2 mm vaccinated mice (Figure 4A), while tumors 218 
regressed in 23,8% of pVAX1-xCT vaccinated mice (Figure 4B). Tumor growth kinetics were slower in the 219 
latter group than in the pVAX1 group, as proven by the significantly shorter time required for tumors to reach 4 220 
or 6 mm mean diameter (20.7±2,7 and 30.7±3,6 days in pVAX1-mxCT vaccinated mice versus 12.9±2 and 221 
20.8±2,5 days in control mice). Anti-xCT vaccination also induced tumor regression in 16% of mice that were 222 
treated when their tumors measured 4 mm mean diameter (Figure 4D), while all tumors in the pVAX1 group 223 
reached 10 mm mean diameter in less than 60 days (Figure 4C). The efficacy of anti-xCT vaccination was then 224 
evaluated against 2 or 4 mm mean diameter tumors obtained when 4T1 tumorsphere derived-cells were injected 225 
s.c. (Figure 4E-H). In 2 mm tumor vaccinated mice, tumors grew rapidly in pVAX1 group (Figure 4E), while 226 
tumor growth kinetics were generally slower and the time required for the tumors to reach 4, 6, 8 or 10 mm 227 
mean diameter was significantly longer in the pVAX1-xCT vaccinated group (10.4±1.3; 15.6±1.6; 20.4±1.3; 228 
23.4±1.2 days in pVAX1-xCT vaccinated mice versus 4.9±0.5; 10±1.1; 14.6±1.0; 17.4±0.8 days in control 229 
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mice). Similarly, the 4 mm tumor vaccinated group displayed slower tumor growth in pVAX1-xCT vaccinated 230 
mice (Figure 4E, H), and the time required for the tumors to reach 6, 8 or 10 mm mean diameter was 231 
significantly longer (9.2±0.9; 13.1±0.9; 17.0±0.5 days in pVAX1-xCT vaccinated mice versus 5.2±0.9; 8.8±1.0; 232 
13.0±1.6 days in control mice), indicating that xCT immunotherapy may be beneficial in various breast cancer 233 
subtypes. 234 
Tumor remission in vaccinated mice might be due to a reduction of CSC frequency as a consequence of the 235 
treatment, as suggested by the decrease in the percentage of Aldefluor+ cells in regressing tumors from mice 236 
vaccinated with pVAX1-xCT plasmid (Figure 4I). Moreover, the cells composing the tumor mass had a 237 
significantly decreased tumorsphere forming ability (Figure 4L) when compared with cells derived from tumors 238 
grown in pVAX1 vaccinated mice. 239 
Anti-xCT vaccination prevents lung metastasis formation  240 
BALB/c mice were vaccinated with pVAX1 or pVAX1-xCT plasmids and i.v. injected with TUBO-derived 241 
tumorspheres to evaluate the effects of anti-xCT vaccination on lung metastasis formation. Metastasis number 242 
was significantly reduced after pVAX1-xCT vaccination, as reported in Figures 5A and B. This anti-metastatic 243 
effect is dependent on the specific antibodies elicited by anti-xCT vaccination, since no effect was observed 244 
vaccinating BALB-µIgKO mice i.v. injected with TUBO-derived tumorspheres (Figures 5C, D). 245 
Anti-xCT vaccination was also able to reduce the number of spontaneous metastases generated from the s.c. 246 
injection of 4T1-derived tumorspheres, either when vaccination was performed before tumorspheres injection 247 
(Figure 5E, F) or when mice already had a 2 mm mean diameter tumor (Figure 5G, H). 248 
Altogether, these findings suggest that anti-xCT vaccination interferes with CSC metastatic properties both in a 249 
preventive and therapeutic setting. This anti-metastatic activity is due to CSC immunotargeting, since no effect 250 
was observed in xCT-vaccinated mice injected with differentiated tumor cells (Supplementary Figure 6A, B) or 251 
in mice vaccinated against Her3 (29) and injected with TUBO-derived tumorspheres (Supplementary Figure 7 252 
A-F). In this model Her3 is not a CSC-specific antigen, since it is equally expressed on TUBO cells and 253 
tumorspheres. 254 
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Anti-xCT vaccination enhances the effect of doxorubicin 255 
In accordance with CSC resistance to chemotherapy (2), TUBO cells display a higher sensitivity to doxorubicin 256 
than tumorspheres (Figure 6A, B). Since xCT is involved in maintaining the intracellular redox balance, thus 257 
counteracting the effects of ROS-generating cytotoxic drugs (13), it is likely that targeting xCT could increase 258 
CSC chemosensitivity. In order to explore this hypothesis in vivo, unvaccinated, pVAX1-xCT and pVAX1 259 
vaccinated mice were i.v. injected with TUBO-derived tumorspheres and either treated with doxorubicin or not. 260 
As shown in Figure 6C, pVAX1-xCT determined a decrease in the number of lung metastases compared to the 261 
control and doxorubicin treated mice and the combination of vaccination and doxorubicin significantly 262 
improved the activity of individual treatments. 263 
Similar results were observed in mice challenged with s.c. injection of TUBO-derived tumorspheres and 264 
subjected to vaccination and chemotherapy when tumors reached 2 mm mean diameter. The tumor regressed in 265 
25% of mice treated with doxorubicin alone (Figure 6D) or in combination with pVAX1 plasmid (Figure 6E), 266 
while the combination of doxorubicin and anti-xCT vaccination stopped tumor progression in 60% mice (Figure 267 
6F).  268 
All together, these data suggest that anti-xCT vaccination may well be an efficient adjuvant treatment for 269 
chemotherapy both in a preventive and in a therapeutic setting. 270 
271 
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Discussion 272 
A key challenge in anticancer therapy is the development of treatments able to both shrink a tumor and kill 273 
CSC, which are resistant to current chemo- and radio-therapies, and are considered the source of tumor 274 
recurrence and metastatic spread. However, the identification of ideal CSC-associated targets is a particularly 275 
tough task since CSC appear to be “moving targets” that switch between different cell states during cancer 276 
progression (30). Hence, antigens that are upregulated in CSC but also present in more differentiated cancer 277 
cells would appear to be outstanding candidates. 278 
A possible candidate with these features is xCT, that we have identified as upregulated in breast Her2+ and 279 
TNBC CSC. Importantly, its expression is not confined to CSC, since we were able to detect its presence on 280 
cancer cells in human hyperplastic mammary glands as well as in IDC, independently from their histological 281 
subtype. xCT possesses all the features of an ideal target for immunotherapy against undifferentiated and more 282 
differentiated cancer cells. This speculation is strengthened by our meta-analyses, performed on human breast 283 
cancer datasets, that link high xCT expression to poor prognosis. 284 
Moreover, xCT expression is not limited to breast cancer. Our analyses, performed on a plethora of healthy and 285 
neoplastic tissues, and data obtained elsewhere in other tumors (7,31,32) have identified xCT as a distinctive 286 
cancer marker and suggested that its targeting may be of benefit in the treatment of a wide range of neoplastic 287 
diseases.  288 
Another important feature of xCT as immunotherapy target is its functional role, which becomes essential in 289 
CSC. Indeed, the impairment of sphere-generation following the pharmacological or genetic downregulation of 290 
xCT reflects the role of this protein in the regulation of CSC self-renewal, indicating that xCT is not a simple 291 
bystander of the stem-like phenotype in breast cancer, but that it also plays a role in CSC biology.  292 
xCT function in CSC self-renewal might be mediated by the regulation of the mechanisms that govern CSC 293 
intracellular redox balance. Although further studies are needed to better define this mechanism in our model, it 294 
has been shown that intracellular ROS concentration can affect CSC viability and self-renewal (33-35). CSC 295 
upregulate the key regulator of the anti-oxidant response Nuclear factor erythroid 2-related factor 2 (36) and 296 
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many anti-oxidant enzymes, such as superoxide dismutase 2, glutathione peroxidases and heme oxygenase 1, 297 
that attempt to maintain intracellular ROS at levels lower than those observed in differentiated cancer cells (37). 298 
In accordance with this, a basal increase in GSH and decrease in ROS levels were observed in tumorspheres as 299 
compared to TUBO cells, which can be explained by xCT upregulation in tumorspheres and proven by the fact 300 
that xCT downregulation reverts this phenotype. 301 
Several authors have advocated the use of xCT as a therapeutic target for pharmacological inhibition using the 302 
administration of SASP, a FDA-approved, anti-inflammatory drug for the treatment of inflammatory bowel 303 
disease, ulcerative colitis and Crohn's disease (38). However, SASP exerts many effects in addition to its ability 304 
to interfere with xCT function, so it cannot be considered a specific xCT inhibitor (39). Although recent 305 
preclinical models demonstrated that SASP impairs cancer growth and metastatic spread via xCT inhibition 306 
(15,17,40), its use in cancer patients is hampered by its low specificity, short bio-availability and numerous side 307 
effects (41). 308 
We have chosen DNA-based antitumor vaccination as our xCT targeting option on the basis of our consolidated 309 
expertise in the field and the considerations stated above. In fact, DNA vaccination is a cost-effective 310 
technology able to induce a significant immune activation against tumor antigens in a specific and well tolerated 311 
way, thus reducing off-target effects (42). This paper sees the first report of xCT being targeted with a DNA-312 
based vaccination strategy that efficiently slows mammary tumor growth and prevents lung metastasis 313 
formation. Our data show that, despite xCT being a self-antigen, DNA vaccination is able to induce an 314 
antibody-based immune response against the tumor; a lack of T-cell response against xCT may be caused by a 315 
thymic depletion of high-avidity T-cell clones, as we have previously reported for the Her2 antigen in the 316 
BALB-neuT model (43). Notably, the anti-tumor effects were lost in B cell deficient mice, confirming the 317 
central role of vaccine-induced antibodies. The anti-tumor effects observed in vivo may result from the CSC 318 
self-renewal and redox balance impairment induced by anti-xCT antibodies, as indicated by our in vitro 319 
observations. This is particularly evident in the inhibition of lung metastasis formation, most likely because 320 
CSC self-renewal is essential for re-initiating growth at the metastatic site (44).  321 
 16
Interestingly, we were not able to detect any vaccine side effect as xCT expression in normal tissues is almost 322 
completely limited to the brain, which can barley be reached by circulating antibodies by virtue of the blood-323 
brain barrier (45). However, it has been reported that xCT may also regulate immune cell functions. In fact, 324 
xCT mediates cystine uptake in macrophages and dendritic cells, which are the only source of free cysteine 325 
release which, in turn, is essential for the antigen-driven activation of T lymphocytes (46). However, by 326 
vaccinating mice against both xCT and Her2, we observed that xCT targeting does not impair the Her2 specific 327 
T cell response (Supplementary Figure 5C, D). The safety of xCT immune targeting is further sustained by the 328 
fact that its genetic ablation in mice does not alter vital biological functions (47).  329 
xCT participate in cancer cells' resistance to a variety of antitumor drugs (16). Its action here is thought to be 330 
linked to its role in intracellular redox balance, as many chemotherapeutic drugs exert their function, at least in 331 
part, by increasing oxidative stress (48). It is worth noting that tumorspheres display significantly increased 332 
resistance to doxorubicin, a drug largely used in breast cancer therapy, as compared to epithelial TUBO cells. 333 
This fits with the observation that CSC are chemoresistant (2), and may reflect the increased expression of xCT 334 
in tumorspheres. In this regard, it has been demonstrated that xCT inhibition promotes the sensitization of tumor 335 
cells to doxorubicin (49,50). In accordance with these findings, we have observed that a combination of anti-336 
xCT vaccination and doxorubicin strongly enhanced the anti-metastatic potential of the individual treatments. 337 
This observation strengthens the translatability of this immunotherapeutic approach to clinical trials, where new 338 
experimental protocols are routinely tested in combination with standard treatments. 339 
In conclusion, we have shown for the first time that xCT immunotargeting is effective in impairing tumor 340 
growth and metastasis formation in vivo. We propose a mechanism by which anti-xCT vaccination exerts its 341 
anti-neoplastic function across two separate, but complementary, fronts: i) a direct effect on CSC through 342 
immune-mediated eradication and ii) inhibition of xCT function on CSC, leading to impairment of tumorigenic 343 
and stem-like properties and their sensitizing to chemotherapy. Moreover, a possible additional anti-cancer 344 
mechanism may occur, by which the anti-xCT antibodies induced by vaccination may suppress the myeloid 345 
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derived suppressor cells that exploit xCT for their inhibitory activity (46). However, this hypothesis is still to be 346 
verified. 347 
Further studies will thoroughly investigate the interactions between chemotherapy and anti-xCT vaccination and 348 
all possible side effects in order to accelerate translation to the clinic, as a safe tool to combat CSC with in 349 
patients is sorely needed.350 
 18
References 351 
1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 352 
2012. CA Cancer J Clin 2012;62(4):220-41. 353 
2. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. The Journal of clinical 354 
investigation 2010;120(1):41-50. 355 
3. Ning N, Pan Q, Zheng F, Teitz-Tennenbaum S, Egenti M, Yet J, et al. Cancer stem cell vaccination confers 356 
significant antitumor immunity. Cancer research 2012;72(7):1853-64. 357 
4. Kwiatkowska-Borowczyk EP, Gabka-Buszek A, Jankowski J, Mackiewicz A. Immunotargeting of cancer stem cells. 358 
Contemporary oncology 2015;19(1A):A52-9. 359 
5. Aurisicchio L, Ciliberto G. Genetic cancer vaccines: current status and perspectives. Expert Opin Biol Ther 360 
2012;12(8):1043-58. 361 
6. Rovero S, Amici A, Di Carlo E, Bei R, Nanni P, Quaglino E, et al. DNA vaccination against rat her-2/Neu p185 more 362 
effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 363 
2000;165(9):5133-42. 364 
7. Lewerenz J, Hewett SJ, Huang Y, Lambros M, Gout PW, Kalivas PW, et al. The cystine/glutamate antiporter 365 
system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid 366 
Redox Signal 2013;18(5):522-55. 367 
8. Gout PW, Buckley AR, Simms CR, Bruchovsky N. Sulfasalazine, a potent suppressor of lymphoma growth by 368 
inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia 2001;15(10):1633-40. 369 
9. Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL, Gillespie GY, et al. Inhibition of cystine uptake disrupts 370 
the growth of primary brain tumors. J Neurosci 2005;25(31):7101-10. 371 
10. Narang VS, Pauletti GM, Gout PW, Buckley DJ, Buckley AR. Suppression of cystine uptake by sulfasalazine inhibits 372 
proliferation of human mammary carcinoma cells. Anticancer Res 2003;23(6C):4571-9. 373 
11. Doxsee DW, Gout PW, Kurita T, Lo M, Buckley AR, Wang Y, et al. Sulfasalazine-induced cystine starvation: 374 
potential use for prostate cancer therapy. Prostate 2007;67(2):162-71. 375 
12. Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, et al. Ferroptosis as a p53-mediated activity during tumour 376 
suppression. Nature 2015;520(7545):57-62. 377 
13. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, et al. CD44 variant regulates redox status in 378 
cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer cell 379 
2011;19(3):387-400. 380 
14. Timmerman LA, Holton T, Yuneva M, Louie RJ, Padro M, Daemen A, et al. Glutamine sensitivity analysis identifies 381 
the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer cell 2013;24(4):450-65. 382 
15. Chen RS, Song YM, Zhou ZY, Tong T, Li Y, Fu M, et al. Disruption of xCT inhibits cancer cell metastasis via the 383 
caveolin-1/beta-catenin pathway. Oncogene 2009;28(4):599-609. 384 
16. Huang Y, Dai Z, Barbacioru C, Sadee W. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and 385 
chemoresistance. Cancer Res 2005;65(16):7446-54. 386 
17. Yoshikawa M, Tsuchihashi K, Ishimoto T, Yae T, Motohara T, Sugihara E, et al. xCT inhibition depletes CD44v-387 
expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. 388 
Cancer Res 2013;73(6):1855-66. 389 
18. Conti L, Lanzardo S, Arigoni M, Antonazzo R, Radaelli E, Cantarella D, et al. The noninflammatory role of high 390 
mobility group box 1/Toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells. FASEB J 391 
2013;27(12):4731-44. 392 
19. Quaglino E, Mastini C, Amici A, Marchini C, Iezzi M, Lanzardo S, et al. A better immune reaction to Erbb-2 tumors 393 
is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. Cancer Res 2010;70(7):2604-12. 394 
20. Donato MT, Martinez-Romero A, Jimenez N, Negro A, Herrera G, Castell JV, et al. Cytometric analysis for drug-395 
induced steatosis in HepG2 cells. Chem Biol Interact 2009;181(3):417-23. 396 
21. Fend L, Accart N, Kintz J, Cochin S, Reymann C, Le Pogam F, et al. Therapeutic effects of anti-CD115 monoclonal 397 
antibody in mouse cancer models through dual inhibition of tumor-associated macrophages and osteoclasts. 398 
PLoS One 2013;8(9):e73310. 399 
 19
22. Ravindranath V. Animal models and molecular markers for cerebral ischemia-reperfusion injury in brain. 400 
Methods Enzymol 1994;233:610-9. 401 
23. Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's 402 
reagent. Anal Biochem 1968;25(1):192-205. 403 
24. Nanni P, Landuzzi L, Nicoletti G, De Giovanni C, Rossi I, Croci S, et al. Immunoprevention of mammary carcinoma 404 
in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. J Immunol 2004;173(4):2288-96. 405 
25. Arigoni M, Barutello G, Lanzardo S, Longo D, Aime S, Curcio C, et al. A vaccine targeting angiomotin induces an 406 
antibody response which alters tumor vessel permeability and hampers the growth of established tumors. 407 
Angiogenesis 2012;15(2):305-16. 408 
26. Grange C, Lanzardo S, Cavallo F, Camussi G, Bussolati B. Sca-1 identifies the tumor-initiating cells in mammary 409 
tumors of BALB-neuT transgenic mice. Neoplasia 2008;10(12):1433-43. 410 
27. Riccardo F, Arigoni M, Buson G, Zago E, Iezzi M, Longo D, et al. Characterization of a genetic mouse model of 411 
lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers. BMC 412 
genomics 2014;15 Suppl 3:S1. 413 
28. Lo M, Wang YZ, Gout PW. The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and 414 
other diseases. J Cell Physiol 2008;215(3):593-602. 415 
29. Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 416 
2008;15(7):413-48. 417 
30. Schwitalla S. Tumor cell plasticity: the challenge to catch a moving target. J Gastroenterol 2014;49(4):618-27. 418 
31. Kinoshita H, Okabe H, Beppu T, Chikamoto A, Hayashi H, Imai K, et al. Cystine/glutamic acid transporter is a 419 
novel marker for predicting poor survival in patients with hepatocellular carcinoma. Oncol Rep 2013;29(2):685-420 
9. 421 
32. Sugano K, Maeda K, Ohtani H, Nagahara H, Shibutani M, Hirakawa K. Expression of xCT as a predictor of disease 422 
recurrence in patients with colorectal cancer. Anticancer Res 2015;35(2):677-82. 423 
33. Singer E, Judkins J, Salomonis N, Matlaf L, Soteropoulos P, McAllister S, et al. Reactive oxygen species-mediated 424 
therapeutic response and resistance in glioblastoma. Cell Death Dis 2015;6:e1601. 425 
34. Sato A, Okada M, Shibuya K, Watanabe E, Seino S, Narita Y, et al. Pivotal role for ROS activation of p38 MAPK in 426 
the control of differentiation and tumor-initiating capacity of glioma-initiating cells. Stem Cell Res 427 
2014;12(1):119-31. 428 
35. Shi X, Zhang Y, Zheng J, Pan J. Reactive oxygen species in cancer stem cells. Antioxid Redox Signal 429 
2012;16(11):1215-28. 430 
36. Ryoo IG, Choi BH, Kwak MK. Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast 431 
carcinoma cells. Oncotarget 2015;6(10):8167-84. 432 
37. Mizuno T, Suzuki N, Makino H, Furui T, Morii E, Aoki H, et al. Cancer stem-like cells of ovarian clear cell 433 
carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in 434 
reactive oxygen species. Gynecol Oncol 2014. 435 
38. Linares V, Alonso V, Domingo JL. Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity. 436 
Expert Opin Drug Saf 2011;10(2):253-63. 437 
39. de la Fuente V, Federman N, Fustinana MS, Zalcman G, Romano A. Calcineurin phosphatase as a negative 438 
regulator of fear memory in hippocampus: control on nuclear factor-kappaB signaling in consolidation and 439 
reconsolidation. Hippocampus 2014;24(12):1549-61. 440 
40. Dai L, Cao Y, Chen Y, Parsons C, Qin Z. Targeting xCT, a cystine-glutamate transporter induces apoptosis and 441 
tumor regression for KSHV/HIV-associated lymphoma. J Hematol Oncol 2014;7:30. 442 
41. Robe PA, Martin DH, Nguyen-Khac MT, Artesi M, Deprez M, Albert A, et al. Early termination of 443 
ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing 444 
malignant gliomas in adults. BMC Cancer 2009;9:372. 445 
42. Aurisicchio L, Mancini R, Ciliberto G. Cancer vaccination by electro-gene-transfer. Expert Rev Vaccines 446 
2013;12(10):1127-37. 447 
43. Rolla S, Nicolo C, Malinarich S, Orsini M, Forni G, Cavallo F, et al. Distinct and non-overlapping T cell receptor 448 
repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J Immunol 449 
2006;177(11):7626-33. 450 
 20
44. Liao WT, Ye YP, Deng YJ, Bian XW, Ding YQ. Metastatic cancer stem cells: from the concept to therapeutics. Am J 451 
Stem Cells 2014;3(2):46-62. 452 
45. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005;2(1):3-14. 453 
46. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit 454 
T-cell activation by depleting cystine and cysteine. Cancer research 2010;70(1):68-77. 455 
47. McCullagh EA, Featherstone DE. Behavioral characterization of system xc- mutant mice. Behav Brain Res 456 
2014;265:1-11. 457 
48. Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer 458 
Ther 2004;3(4):294-300. 459 
49. Narang VS, Pauletti GM, Gout PW, Buckley DJ, Buckley AR. Sulfasalazine-induced reduction of glutathione levels 460 
in breast cancer cells: enhancement of growth-inhibitory activity of Doxorubicin. Chemotherapy 2007;53(3):210-461 
7. 462 
50. Wang F, Yang Y. Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to 463 
doxorubicin. Breast cancer research and treatment 2014;147(1):203-10. 464 
 465 
466 
 21
Figure legends 467 
Figure 1. xCT expression in breast CSC and tumors. (A) FACS analysis of xCT expression in TUBO cells 468 
and P1 to P3 tumorsphere passages over six independent experiments. (B) Representative density plots of xCT 469 
and Sca-1 expression on TUBO and tumorspheres. Numbers show the percentage of cells in each quadrant. (C) 470 
Representative immunofluorescence staining of xCT, Sca-1, OCT4 and Thy1.1 on tumorspheres. DAPI stains 471 
the nucleus. Scale bar 20 μm. (D) Representative density plots of xCT expression in TUBO cells stained with 472 
CD44 and CD24. (E) FACS analysis of xCT espression in HCC-1806, MDA-MB-231 and 4T1 cells and their 473 
derived tumorspheres over three independent experiments. *P<0.05, **P<0.01, ***P<0.001, Student's t-test. 474 
(F) Immunofluorescence of xCT expression (red) in normal breast, hyperplastic and IDC breast carcinoma. 475 
Scale bar 20 μm. (G) Percentage of xCT+ samples in normal mammary gland and in TNBC, Her2+ or 476 
ER/PR+Her2- breast cancer subtypes. 477 
Figure 2. xCT regulates CSC self-renewal and the intracellular redox balance. (A, B) MTT assay of the 478 
cytotoxic effect exerted by scalar doses of SASP or by anti-xCT siRNAs on (A) TUBO and (B) tumorspheres. 479 
(C) Sphere generation ability relative to untreated cells of tumorspheres incubated with SASP. (D) Sphere 480 
generation ability of tumorspheres incubated with siRNAs to xCT, scrambled siRNA or not at all shown as 481 
tumorsphere number/103 plated cells. (E, F) FACS analysis of xCT and CSC marker expression in spheres 24 482 
hours after transfection with siRNA to xCT or scrambled siRNA. (E) Gray histograms show xCT expression, 483 
open histograms show the background of negative control IgG stained cells from one representative experiment. 484 
(F) Relative expression (%) of xCT+, Sca-1+ and CD44high/CD24low cells in tumorsphere-derived cells 485 
transfected with siRNAs to xCT (black bars) compared to cells transfected with scrambled siRNA (dashed line). 486 
(G, H) GSH (G) and ROS (H) levels in TUBO cells and their derived tumorspheres after either seeding in 487 
normal conditions, transfection with siRNAs to xCT or scrambled siRNA over three independent experiments. 488 
*P<0.05, **P<0.01, ***P<0.001, Student's t-test.  489 
Figure 3. Vaccine-induced antibodies target CSC and affect their self-renewal and ROS flux. (A-C) 490 
TUBO-derived tumorsphere or (E-G) NIH/3T3 cell staining by antibodies present in the sera of BALB/c mice 491 
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vaccinated with pVAX1 or pVAX1-xCT, analyzed by FACS. Results are reported as (A, E) the mean 492 
fluorescence intensity (MFI) from 7 mice per group, (B, F) the percentage of positive cells, and (C, G) two 493 
representative dot plots. (D, H) Representative images of (D) TUBO-tumorspheres or (H) NIH/3T3 cells stained 494 
with IgG purified from sera of mice vaccinated with pVAX1 or pVAX1-xCT. Scale bar 20 µM. (I) Sphere 495 
generating ability of tumorspheres incubated for 5 days with IgG purified from the sera of mice vaccinated with 496 
pVAX1, pVAX1-xCT or not at all. Graph shows tumorsphere number/103 plated cells. FACS analysis of (L) 497 
CSC marker expression or (M) ROS production in tumorspheres incubated for 5 days with IgG purified from 498 
the sera of vaccinated mice or not at all, reported as (D) percentage of positive cells or of the (E) DCF MFI 499 
from four independent experiments. *P< 0.05, **P<0.01, Student's t-test. 500 
Figure 4. Anti-xCT vaccination delays CSC-induced tumor growth in vivo. 501 
BALB/c mice were s.c. challenged with tumorspheres derived from either (A-D) TUBO or (E-H) 4T1 cells and 502 
electroporated with (A, C, E, G) pVAX1 or (B, D, F, H) pVAX1-xCT plasmids when their tumor reached (A, 503 
B, E, F) 2 or (C, D, G, H) 4 mm mean diameter. Each black line depicts the growth of a single tumor. Data were 504 
cumulated from three independent and concordant experiments. Statistically significant differences in mean 505 
time required for pVAX1-xCT group and pVAX1 group tumors to reach 4, 6, 8 or 10 mm mean diameter are 506 
indicated by dashed gray lines. (I, L) Analysis of (I) the percentage of Aldefluor+ cells in tumors explanted from 507 
vaccinated mice challenged s.c. with TUBO-derived tumorspheres and (L) number of tumorspheres generated 508 
in vitro by cells from the same tumors. *P<0.05, **P<0.01.  509 
Figure 5. Anti-xCT vaccination reduces CSC-generated lung metastasis formation. (A-B and E-H) 510 
BALB/c and (C, D) BALB-µIgKO mice were vaccinated with either pVAX1 or pVAX1-xCT plasmids (A, C, 511 
E) before tumorspheres injection or (G) when mice had 2 mm mean diameter tumor. (A, C, E, G) Number of 512 
lung metastases in mice challenged (A, C) i.v. with TUBO- or (E, G) s.c. with 4T1-derived tumorspheres and 513 
enumerated (A, C) 20 days later or (E,G) when the primary tumor reached 10 mm mean diameter. (B, D, F, H) 514 
representative images of lung metastases after H&E staining **P<0.01, ***P<0.001, Student's t-test. 515 
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Figure 6. Anti-xCT vaccination enhances the effect of doxorubicin in vivo. (A, B) MTT assay of the 516 
cytotoxic effect exerted by incubation with scalar doses of doxorubicin in (A) TUBO and (B) tumorspheres. (C) 517 
Number of lung metastases in mice challenged i.v. with TUBO-derived tumorspheres and either vaccinated or 518 
not with pVAX1 and pVAX1-xCT plasmids alone or in combination with doxorubicin administration. (D-F) 519 
Tumor growth curves of BALB/c mice s.c. injected with TUBO derived tumorspheres and treated with 520 
doxorubicin in combination with (E) pVAX1 or (F) pVAX1-xCT vaccination when their tumors reached 2 mm 521 
mean diameter. Treatments were repeated the week later. Each black line depicts the growth of a single tumor. 522 
Student's t-test. *P<0.05, **P<0.01, ***P<0.001, Student's t-test. 523 
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